◀ Back to MTOR

BCR — MTOR

Text-mined interactions from Literome

Donahue et al., Eur J Immunol 2007 : We used flow cytometry and magnetic cell sorting to examine the requirement for PI3K and mTOR in responses of splenic B cell subsets to BCR and LPS stimulation ... BCR mediated mTOR activation in both subsets is inhibited by wortmannin, though less strongly in MZ cells
Joha et al., Oncogene 2012 (Leukemia, Myelogenous, Chronic, BCR-ABL Positive) : Our findings provide new mechanistic insights into the role of mTORC2 in BCR-ABL ( + ) cells and indicate that regulation by GILZ may influence TKI sensitivity
Redig et al., Leukemia & lymphoma 2011 (Leukemia, Myelogenous, Chronic, BCR-ABL Positive) : A large body of evidence has established that BCR-ABL regulates engagement and activation of mammalian target of rapamycin (mTOR) and mitogen activated protein kinase ( MAPK ) signaling cascades
Sheng et al., Blood 2011 (Cell Transformation, Neoplastic...) : We find that BCR-ABL , through PI3K/AKT/FOXO4 signaling, transcriptionally up-regulates ATF5 expression and that ATF5, in turn, stimulates transcription of mammalian target of rapamycin ( mTOR ; also called mechanistic target of rapamycin ), a well established master negative-regulator of autophagy